A methionine substitution at lysine 27 on histone H3 variants (H3K27M) characterizes ~80% of diffuse intrinsic pontine gliomas (DIPG) and inhibits PRC2 in a dominant negative fashion. Yet, the mechanisms for this inhibition and abnormal epigenomic landscape have not been resolved. Using quantitative proteomics, we discovered that robust PRC2 inhibition requires levels of H3K27M greatly exceeding those of PRC2, seen in DIPG. While PRC2 inhibition requires interaction with H3K27M, we found this interaction on chromatin is transient with PRC2 largely being released from H3K27M. Unexpectedly, inhibition persisted even after PRC2 dissociated from H3K27M-chromatin suggesting a lasting impact on PRC2. Furthermore, allosterically activated PRC2 is particularly sensitive to K27M leading to a failure to spread H3K27me3 at distinct foci. In turn, levels of Polycomb antagonists such as H3K36me2 are elevated suggesting a more global, downstream effect on the epigenome. Together, these findings reveal the conditions required for H3K27M-mediated PRC2 inhibition and reconcile seemingly paradoxical effects of H3K27M on PRC2 recruitment and activity.
INTRODUCTION
Histones form the core DNA packaging material in the nucleus. Even slight alterations in their amino acid composition can have dramatic consequences on chromatin structure affecting gene expression and genome integrity (1). One of the most striking examples is the lysine-to-methionine substitution at residue 27 on canonical histone H3.1 or its variant H3.3 (H3K27M). These mutations were discovered in ~80% of diffuse intrinsic pontine gliomas (DIPG), one of the most deadly and difficult-to-treat pediatric cancers (2) . Despite affecting only one of 15 copies of the H3 genes, the presence of H3K27M significantly impairs the activity of PRC2, leading to a drastic reduction and re-distribution of di-and tri-methylation of H3K27 [H3K27me2 and -3; (3-6)] in the affected cells. These effects of H3K27M on PRC2, as well as those on the chromatin landscape have been linked to oncogenic transcriptional programs that give rise to the cancer stem cell-like and proliferative properties of DIPG (4, 7, 8) . Therefore, understanding the underlying mechanisms of how H3K27M affects PRC2 and the global epigenetic landscape is imperative for understanding DIPG and ultimately, devising strategic ways to overcome the oncogenic potential of H3K27M.
Following the discovery of H3K27M, a hypothesis emerged suggesting that H3K27M traps and sequesters PRC2, thereby diminishing its activity (3) . Supporting evidence came from the observation that PRC2 has a higher affinity for H3K27M relative to H3K27WT peptides and nucleosomes (4, 9) . Moreover, structural studies revealed that H3K27M occupies the catalytic SET domain of EZH2, preventing the hydrolysis of the methyl donor S-adenosylmethionine (SAM) and the release of EZH2 (3, 4, 9) . However, in vivo studies indicate that the genomic localization of H3K27M is often inversely correlated with PRC2 occupancy, challenging the idea that H3K27M sequesters PRC2 on chromatin (6, 10, 11) . Notably, despite a drastic loss in H3K27me3 in affected cells, some loci retained PRC2 and H3K27me3 at abnormally high levels in H3K27M-expressing cells (4, 5, 12) . Additional layers of complexity came from studies showing that H3K27M does not have consistent effects in all cell types (7, 8) nor is it able to strongly interact with PRC2 in all chromatin contexts (6, 13) . Therefore, a model whereby H3K27M stably sequesters PRC2 on chromatin cannot explain all observations, indicating that further study is required to resolve these disparate observations and to uncover the mechanism(s) by which H3K27M affects PRC2 and the chromatin landscape in DIPG. This study aims to reconcile these findings by combining isogenic and patient-derived model systems to better understand the dynamic and nuanced impact of H3K27M on PRC2 while placing those effects in the molecular and broader chromatin context.
RESULTS

H3K27M to PRC2 ratio dictates the degree of PRC2 inhibition
Perhaps the most studied hypothesis for dominant negative inhibition of PRC2 by H3K27M is that H3K27M sequesters PRC2, preventing it from methylating the majority of H3K27WT nucleosomes (3, 4, 9, 14) . This hypothesis relies on two assumptions: that H3K27M is more abundant than PRC2 and that PRC2 has a higher affinity for H3K27M-than H3K27WT-containing nucleosomes. Therefore, precise quantification of PRC2 relative to H3K27 methylation and H3K27M levels in DIPGs and comparable cell types is essential for understanding how the cellular stoichiometry of these factors contributes to cellular sensitivity to H3K27M. We hypothesized that the levels of PRC2 might render DIPG particularly sensitive to H3K27M given their profound loss in H3K27me2-3 relative to other brain tumors and cell types in the neural lineage ( Fig. 1A) .
Testing this hypothesis required a quantitative measure of PRC2 molecules per cell, leading us to develop a mass spectrometry (MS) parallel reaction-monitoring assay (15) . Briefly, PRC2 core proteins (EZH2, EED, and SUZ12) were quantified with a targeted method using heavy isotope-labeled synthetic peptides as internal standards ( fig. S1A-S1C) . Our approach revealed a wide range of PRC2 levels across different cell types, with CRISPR-generated H3K27M (on H3F3A) E14 mouse ESCs (mESC) containing relatively high PRC2 levels (~150,000 PRC2 molecules/cell) ( Fig. 1B and fig. S1D ). In our isogenic mESC and 293 TREX system below we chose H3.3K27M as it is the most frequently occurring H3K27M mutation (2) . Interestingly, H3K27M DIPG (both H3.1-and H3.3K27M DIPGs) were at the lower end of the spectrum (~5-10,000 PRC2 molecules/cell; fig. S1D). By comparing the levels of PRC2 with those of H3K27M as determined by relative quantitative histone MS, we observed that H3K27M-bearing DIPG exhibited ~100-fold excess of H3K27M over PRC2 ( Fig. 1B and see Table S1 for details on cell lines). In accordance, H3K27M-bearing DIPGs showed a robust loss in H3K27me2-3 deposition relative to WT DIPG ( Fig. 1B) . Similarly, 293 TREX cells with inducible expression of H3K27M (H3.3K27M) also showed a large excess of H3K27M relative to PRC2 (over 200-fold) and a substantial deficit in H3K27me2-3. However, mESC harboring H3.3K27M showed only a modest loss in H3K27me2/-3, relative to WT mESC. Given that H3K27M was only in ~10-fold excess of PRC2 in mESC, the results suggested that H3K27M must be largely in excess of PRC2 to achieve the robust decrease in H3K27me2-3 seen in DIPG and other cell types. Importantly, these results are consistent with previous speculation that high amounts of a Kto-M mutation is needed to inhibit various histone methyltransferases (3, 16) .
To test whether shifting the relative abundance of H3K27M and PRC2 during lineage commitment could alter sensitivity to H3K27M inhibition, we differentiated H3.3K27M mESC as described above into cervical motor neuron precursors [mNEURON; (17) ] (Fig. 1C) . Our quantitative mass-spec revealed that PRC2 decreased as cells proceeded down the motor neuron lineage to levels consistent with those seen in DIPG [5-10,000 molecules/cell; fig S1] . Importantly, we observed that K27M produced a greater loss of H3K27me2/-3 in mNEURON than was seen in undifferentiated mESC ( Fig. 1D) . Although we cannot rule out the contribution of an unknown factor(s) during the differentiation process, these results together with those analyzing the quantitative H3K27M:PRC2 ratio in different cells, demonstrate that the critical force for the H3K27me3 reduction is due the large excess of K27M over PRC2. These observations are consistent with K27me2/-3 loss when the H3K27M:PRC2 ratio is high, which we tested directly using a histone methyltransferase assay (HMT) in a fully biochemically reconstituted system (Fig. 1E ). The addition of increasing amounts of recombinant oligonucleosomes comprising H3K27M gave rise to heightened sensitivity of PRC2 to inhibition, while the control using oligonucleosomes where lysine-27 was mutated to alanine (H3K27A) were ineffectual ( Fig. 1E) . Together, the quantitative approach measuring H3K27M:PRC2 ratio in different cell lines including patientderived DIPG model systems, the in vitro differentiation studies together with the biochemical approach, revealed that cells containing low amounts of PRC2, relative to H3K27M such as DIPG, motor neurons and 293 TREX are sensitive to H3K27M-mediated inhibition of PRC2 activity.
PRC2 is transiently recruited to H3K27M-containing chromatin
Given the high excess of H3K27M to PRC2 in DIPG ( Fig. 1B) and the higher affinity of PRC2 for H3K27M in vitro, H3K27M would be expected to sequester all PRC2 in a DIPG cell (3, 9, 16) . However, the following observations argue against this assumption: 1) PRC2 and H3K27M often do not co-localize on chromatin under some conditions of steady-state H3K27M expression, as measured by ChIP (6, 10, 18) and 2) H3K27me3 can be retained at specific loci as well as redistributed in H3K27M cells (4-6, 10, 12) . Reasoning that the steady-state dynamics between H3K27M and PRC2 reflect only the outcome of this dysregulated process, we sought a means to detect changes in the interaction between H3K27me3 and PRC2 and subsequent effects on PRC2 as a function of the rate of H3K27M deposition. To this end, we used an inducible expression system in 293 TREX cells to monitor the early and later events following H3K27M expression ( Fig. 2A ). This inducible system recapitulated the global loss of H3K27me2/-3 seen in H3K27M-bearing DIPG ( Fig. 2B & 1A) . Spike-in normalized ChIP-seq experiments across this time course revealed that PRC2 primarily co-localized with H3K27M at early time points, namely after 6 and 12 hr of expression, but was largely excluded from H3K27M sites at the late, 24 hr time point ( Fig. 2C, left panel) . Genome-wide analysis indicated that there are nearly 1,500 PRC2 occupied domains unique to the 6 and 12 hr time points that are not present at 24 hr ( Fig. 2C, right panel) . Importantly, those early PRC2 loci are only seen in H3K27M, but not H3K27WT-expressing cells and colocalized with H3K27M ( Fig. 2C) . Combined with the higher affinity of PRC2 for H3K27M nucleosomes [(4) and see below] and peptides (9) , our results demonstrated that H3K27M-containing nucleosomes transiently recruit PRC2 to loci not typically occupied by PRC2 in a wild-type setting, leading to aberrant deposition of PRC2 early after H3K27M expression ( Fig. 2) .
Given the transient nature of PRC2 recruitment to H3K27M, numerous factors might contribute to its eviction including the known PRC2 antagonist, H3K36 methylation, especially when it occurs directly adjacent to H3K27M (i.e., in cis). Indeed, western blot analysis of extracts derived from the inducible 293 TREX system revealed enrichment of H3K36me2 on H3.3K27M histones, supporting their co-occurrence in cis, which coincided with a loss of H3K27me2/-3 ( Fig. 2B) . This was particularly evident in H3K27M-bearing DIPG where mass-spectrometry revealed that H3K36me2 was overwhelmingly the predominant modification adjacent to H3K27M regardless of whether it was H3.1-or H3.3K27M ( fig. S2A ). Importantly, in our time course studies, a strong co-occurrence in cis of H3K36me2 and H3K27M emerged at 24 hr at which time EZH2 occupancy at H3K27M-containing loci is lost, relative to earlier time points ( Fig. 2B) . Therefore, eventual PRC2 eviction and stable exclusion from K27M loci might be related to H3K36me2 deposition, presumably by preventing PRC2 interaction with the H3 N-terminal tail (19) (20) (21) (22) . Other antagonistic modifications such as histone acetylation might also contribute as has been suggested by others [ (6, 13) and see our data below]. In a broad sense, the deposition of H3K27M largely into transcriptionally active regions in both the isogenic K27M 293 TREX and K27M DIPG cells themselves ( fig. S2B) , suggests a dynamic environment wherein histone modifications associated with transcription activity [this study and (6, 13) ], histone turnover (23) and even nascent mRNA might lead to the failure of K27M to stably recruit PRC2 [i.e., the eviction of PRC2 (11, 24) ]. While we cannot exclude the possibility that the release of PRC2 from H3K27M arises from a more direct effect on PRC2 itself (see Discussion), we expect that future studies will find that the interaction and release of PRC2 from H3K27M is determined by the interplay between the local chromatin environment and structural changes to PRC2 itself.
Persistent inhibition of PRC2 after its dissociation from H3K27M
We next sought to better understand the impact of H3K27M on PRC2 activity at more typical PRC2 target sites. First, we identified 616 broad PRC2 (EZH2) domains present in both H3K27M and H3K27WT cells across all time points and found that despite the retention of EZH2 at a subset of genes at 24 hr in H3K27M cells, a global loss of H3K27me3 was evident ( Fig. 3A and fig. S3 for visualization of the broad domains). As the cells progressed attaining steady-state levels of H3K27M, the loss in H3K27me3 was even greater in magnitude, despite the retention of EZH2 and the lack of H3K27M enrichment at those same sites after 72 hr of H3K27M expression ( Fig. 3B) . Together, these results are consistent with recent work showing that loci depleted of H3K27me3 in H3K27M cells have equal PRC2 occupancy, as well as emerging evidence that PRC2 recruitment can be uncoupled from its enzymatic activity [ (5, 25) and see below].
We next investigated whether the interaction of PRC2 with H3K27M-containing nucleosomes might have a lasting impact on its function. This was motivated by our observations that; 1) newly expressed K27M deposits at sites that are not usually regulated by PRC2 and PRC2 is transiently recruited at these new sites, as well as, 2) some PRC2 regulated genes maintain PRC2, but its activity is reduced in H3K27M cells ( Fig. 2 and 3) . To study this, we expressed tagged-PRC2 in H3K27M-and H3K27WT-expressing 293 TREX cells ( fig. S4A and B) . PRC2 was then purified using a combination of conventional and tandem-affinity chromatography yielding PRC2 in correct stoichiometry between samples ( Fig. 4A) . Most importantly, H3K27M was not detected by western blotting and mass spectrometry analysis in the purified PRC2 fractions ( Fig. 4A and fig. S4C ). Interestingly, we found that the catalytic activity of PRC2 purified from H3K27M-expressing cells was markedly decreased relative to PRC2 purified from H3K27WT cells and this inhibition was SAM dependent (Fig. 4B ) which is consistent with the previous observation demonstrating that SAM is necessary for inhibition of the methyltransferase by K-to-M mutation on histone H3 (26) . This lasting H3K27M inhibitory effect on PRC2 was also observed using a system reconstituted with all recombinant components, including PRC2 comprising only its 4 core subunits (EZH2, EED, SUZ12 and RBAP48; Fig. 4C ) and oligonucleosomes formed with bacterially-expressed histones ( Fig. 4D) . After release from H3K27M-containing oligonucleosomes, the resultant PRC2 was generally less active ( Fig. 4E) , in line with a wide-spread attenuation of H3K27me2/-3 in K27M DIPG. Given that lasting PRC2 inhibition is seen in vivo as well as within a fully recombinant system, we speculate that H3K27M-containing chromatin alters the core PRC2 complex through a stable conformational change (see Discussion).
Inhibition of allosteric activation of PRC2 and spreading of H3K27me3
We noted a strong similarity between the phenotype of H3K27M cells in which PRC2 is recruited but exhibits diminished activity and that of PRC2 mutants that are deficient in allosteric activation (25) . Thus, we next tested whether H3K27M may preferentially impair allosteric activation of PRC2. To accomplish this, we incubated PRC2 with increasing amounts of the allosterically activating H3K27me3 peptide in the presence of SAM and nucleosomes comprising either H3K27M or control H3K27A (HA-tag on H2A; Fig 5A) . PRC2 activity was subsequently assessed by adding WT nucleosomes (distinguished by a C-terminal FLAG-tag on H3; Fig.  5A ). Strikingly, while there was little difference in the absence of H3K27me3 peptide, PRC2 was refractory to stimulation by H3K27me3 in the presence of H3K27M nucleosomes (Fig. 5B) . Furthermore, the presence of H3K27me3 selectively increased the binding affinity of PRC2 towards H3K27M-containing chromatin ( Fig. 5C) . Combined, these results indicate that the allosterically activated form of PRC2 (25, 27) binds stronger to H3K27M and that PRC2 catalysis is more sensitive to H3K27M.
To examine whether a similar defect in catalysis exists in H3K27M-bearing glioma, we used an internal spike-in normalized ChIP-seq protocol and directly compared H3K27me3 deposition in two independent H3K27M DIPG and H3K27WT glioma cell lines (selected based on being pediatric WHO Grade IV, matched culture conditions and IDH1 wild-type). Interestingly, the H3K27me3 peaks in the H3K27M cells appeared sharper and larger in magnitude than those observed in WT cells ( Fig. 5D-left) . Genome-wide analysis confirmed these observations, and more importantly revealed that the "remaining" H3K27me3 peaks in H3K27M glioma were not subject to spreading into large repressive H3K27-me-containing domains as observed in WT cells, a process likely dependent on PRC2-mediated allosteric activation (25, 27) ( Fig. 5D-right) . Our results are consistent with a broader mechanism of K-to-M substitutions as evidenced in S. pombe wherein H3K9M induces a gain in H3K9me3 and its methyltransferase (Clr4) at H3K9me3 nucleation sites, while H3K9me3 spreading across domains is lost (16) . Our results account for the recent descriptions of H3K27M isogenic and glioma cells wherein there is a focal gain in H3K27me3 at previously established PRC2 target loci that are CpG island-dense (5, 7, 8, 12) . Thus, by impairing allosteric activation of PRC2 and thus spreading of H3K27me3 (25, 27) , H3K27M achieves both a global loss of H3K27me3 and yet, a focal accumulation of H3K27me3 at PRC2 recruitment sites.
Altered histone modification landscape in H3K27M DIPG
Given the widely documented cross-talk among histone modifications, we tested whether the presence of H3K27M might affect the global histone modification landscape that could further affect PRC2 activity, resulting in an aberrant epigenetic profile in DIPG. In H3K27M-bearing DIPGs, a few histone modifications such as H3K27 acetylation have already been shown to increase in concert to the decrease in H3K27me3 (3, 4, 12, 28) . However, a systematic analysis of the histone modification profile of DIPGs has so far been hampered, perhaps by the scarcity of suitable WT controls given that the majority of DIPGs carry the H3K27M mutation. Here, we were able to utilize the same quantitative histone modification MS approach as above on a panel of human primary H3K27WT glioma lines, two different H3K27WT DIPGs and four different H3K27M DIPGs to identify global histone modification alterations against a relevant control background. Consistent with other studies was a largescale gain of histone acetylation in H3K27M DIPG ( fig. S5 ). However, we observe that the largest gain of acetylation is on the H4 tail (~20% gain). This finding suggested that histone acetylation events beyond the relatively smaller net gain in H3K27 acetylation (~ 0.3%) reported here ( fig. S5 ) and elsewhere (3, 6, 29) might be important drivers of the disease.
The most striking result was a significant gain in H3K36me2 within H3K27M DIPG cells ( Fig. 6A) . ChIPseq indicated higher levels of H3K36me2 on H3K36me2-target genes in K27M DIPG relative to WT ( Fig. 6B and C). In our isogenic H3K27M 293 TREX system, we further observed an invasion of H3K36me2 largely into former PRC2 domains that lost H3K27me3 ( fig. S6) . These alterations in the euchromatic H3K36me2-domains and the corresponding heterochromatic H3K27me3-domains are reminiscent of sarcoma cells that express H3K36M and exhibit dampened H3K36 methyltransferase(s) activity leading to abnormal deposition of H3K27me3 (30) . Due to the heterogeneity of pediatric glioma cell culture lines, we selected a WT (DIPG X) and a K27M (DIPG XIII) cell line to compare by RNA-seq as these are better matched with respect to both being DIPG, as well as their growth properties as non-adherent tumorspheres. As expected, the regions that gain H3K36me2 in K27M DIPG also show upregulation of those genes ( fig. S7A ) and are associated with proneuronal phenotypes, cancer pathways and cell adhesion phenotypes seen in H3K27M DIPG by KEGG pathway analysis ( fig. S7B) . Thus, in each of these cases, the K-to-M mutations disrupt heterochromatic and euchromatic domains that have potential to drive aberrant gene expression patterns important for proliferation, cancer stem cell properties, and oncogenesis (4-7).
DISCUSSION
A primary challenge in the H3K27M field has been to resolve the contradictory observations indicating that PRC2 has a high affinity for H3K27M peptides, yet PRC2 and H3K27M are often mutually excluded from chromatin in K27M DIPG (4, 6, 9, 10) . Our studies revealed that interaction of H3K27M with PRC2 is a dynamic process that cannot be captured by static, steady-state approaches. Namely, there is an initial phase after H3K27M is expressed and incorporated into chromatin, followed by PRC2 recruitment to H3K27M-containing chromatin, presumably due to its higher affinity towards H3K27M (Fig. 2C ). However, in the next phase, PRC2 is released from H3K27M as they do not co-localize at steady state conditions in both isogenic 293 TREX systems (e.g., this study, Fig. 2 & 3) as well as in the H3K27M DIPG themselves (6) . This dynamic model therefore accommodates both the finding of high H3K27M and PRC2 affinity in select assays as well as their failure to stably colocalize on chromatin in cells. In line with the more fluid effect of H3K27M is a recent high-resolution imaging study suggesting that although H3K27M does not change the amount of PRC2 bound to chromatin, it can increase the time needed for PRC2 to find and select its target chromatin loci (31) . An implication of these studies is that PRC2 is not stable on H3K27M chromatin, an effect with striking resemblance to the recently proposed "hit and run" hypothesis of PRC2 where core PRC2 devoid of "stabilizing" components such as MTF2 and JARID2 is less stable on chromatin (27) . These findings therefore set the stage for future proteomic studies designed to test whether it is indeed decreased association of PRC2 with these stabilizing co-factors or other more direct effects of H3K27M on the PRC2 core complex that drives the transient H3K27M-PRC2 interaction, or alternatively a rapid change in the epigenome by the gain of H3K36me2 (these studies) as well as of H3K27ac (6) .
One of the most unexpected findings in our study was a second, previously unknown mode of PRC2 inhibition that apparently persists even after its dissociation from H3K27M (Fig. 4) . Importantly, this mode of inhibition was more severe as the concentration of SAM increased, suggesting that the PRC2 released from K27M might have a defect in SAM turnover, thereby delaying catalysis (9) . The other possibility is that H3K27M might inhibit EZH2 automethylation (32, 33) , eventually influencing the activity of PRC2 on chromatin. Recent studies from our group and others revealed novel automethylation sites on EZH2 and highlighted the impact of EZH2 automethylation on PRC2 activity (32, 33) . It is intriguing to speculate that EZH2 automethylation could stably change the conformation of the PRC2 complex thereby altering its activity on chromatin. Seemingly in line with a lasting effect of H3K27M on PRC2, is a recent study showing that while the levels of PRC2 bound to chromatin do not change, the search time of PRC2 for chromatin is increased in cells that express H3K27M (31) . While other variables such as lower H3K27me3 levels may affect PRC2 search time, it is consistent with our findings that there may be a lasting change in PRC2 following its dissociation from H3K27M-containing chromatin that affects its later function.
Our mechanistic studies were also able to give insight into the paradoxical observation that despite a widespread loss in H3K27me3, there are a smaller number of loci that actually gain H3K27me3 in DIPG at steady state (4, 5, 7, 12) . We showed that H3K27M has a strong inhibitory effect on the allosteric activated form of PRC2 (Fig. 5 ). To put our finding in the context of the current literature, the initial step of allosteric activation of PRC2 is its binding to H3K27me3, the terminal enzymatic product of PRC2, through its essential EED subunit.
The result is a conformational change in EZH2 that stabilizes its catalytic SET domain leading to a substantial enhancement of its HMT activity (9, 34) . This positive feedback loop facilitates the spreading of H3K27me2/-3 from PRC2 recruitment sites (27, 35) . Here, we observed that allosterically activated PRC2 preferentially binds to H3K27M nucleosomes (Fig. 5C ), an effect similar to one previously reported using structural studies (9) . Yet, we found that the strongest inhibitory effect of H3K27M was on the allosterically activated PRC2, implying a blockade of the positive feedback activation loop. The net effect is that PRC2 is still recruited to strong polycomb foci in H3K27M cells. However, PRC2 is not allosterically activated and thus, H3K27me3 does not spread, leading to the accumulation of H3K27me3 at strong PRC2 foci. Together, these modes of PRC2 inhibition shed light onto how gains of H3K27me3 can occur at select regions despite the more global loss in PRC2 activity.
In the context of the broader chromatin landscape in H3K27M, we showed both large gains in histone acetylation ( fig. S5 ) as previously reported (3, 6, 12) , as well as the novel and robust increase in another transcriptionally active histone modification, H3K36me2 (Fig. 6) . Based on recent studies suggesting that disrupting the balance of PRC2 activity and H3K36 methylation levels can drive oncogenesis, we speculate that high H3K36me2 might represent a core feature of H3K27M DIPG (30) . It is worth noting that given the heterogeneity present within K27M DIPG compared to WT glioma, more work is needed to better understand the precise contributions of H3K36me2 to transcriptional programs that might drive oncogenesis specifically in K27M DIPG. Such studies of the downstream effects of H3K36me2 will likely be fruitful since readers of this modification as well as the enzymes that place this modification are potentially drugable therapeutic vulnerabilities in DIPG. Indeed, targeting oncogenic chromatin features, such as residual PRC2 activity as well as the gain of histone acetylation marks and their readers, have been shown to decrease the hallmarks of DIPG growth and aggression in preclinical models (2, 5, 6, 29, 36) . Therefore, combining biochemistry with mechanistic studies, proteomics, and DIPG disease model systems promises to not only shed light on the underlying biology, but also to reveal novel targets, alone or in combination, for therapeutic intervention in this otherwise intractable disease.
MATERIALS AND METHODS
Cell Culture Models and Tissue Preparation.
A complete list of cell lines and in vivo H3K27M model systems can be found in Table S1 . Culture methods are described briefly, below.
Mouse Stem Cells and Motor Neuron Differentiation. Mouse E14 ESC were cultured as described previously (17) . Differentiation to cervical motor neurons is detailed in Narendra et al., 2015, but briefly, ESC were plated at low density in the absence of mitogenic factors to form embryoid bodies. Two days later, media was supplemented with 1 µM retinoic acid and 0.5 µM smoothened agonist. Cells were harvested 4 days later with one media replenishment at 2 days.
Human Brian Tumor Models. Patient-derived glioma lines, including DIPG lines (see Table S1 for source), were cultured in tumor stem cell media as described (37, 38) . Human neural stem cells were derived and cultured as described previously (39) . NYU patient derived tumor cell line generation has been approved by the NYU Institutional Review Board (IRB# S15-01228). Pathological diagnoses of primary tumors from which cell lines were derived, were performed by a board certified neuropathologist (M.S.) and molecular characteristics were established at an NYU CLIA certified molecular pathology laboratory. Furthermore, relevant tumor sample collection and molecular profiling were approved by the NYU Institutional Review Board (IRB#: S12-00865 and S14-00948, respectively). All human tumor samples were reviewed and diagnosis performed by a board certified neuropathologist (M.S.) in a CLIA certified pathology laboratory.
Generation of Isogenic Cell Lines
mESC Model. The H3K27M mutation was introduced into the H3F3A locus through CRISPR-Cas9 engineering as described in Narendra et al., 2015. Briefly, gRNA directed at H3F3A were designed using the http://crispr.mit.edu/ design tool and cloned into the SpCas9-2A-GFP vector (Addgene Plasmid #48138). mESC were co-transfected with the Cas9, guide RNA and donor DNA template to promote homology directed repair resulting in an M substitution at K27 of H3F3A (i.e., AAG to ATG). Cells containing the Cas9 vector were selected by GFP+ FACS sorting and single cells were plated at low density. Individual colonies were picked 5-7 days later. Individual clones bearing the mutation were harvested and genotyped using Sanger sequencing. Colonies positive for the H3F3A K27M substitution were passaged at least 5 times to confirm purity of the population.
293 TREX Model. Cells were cultured using standard media (DMEM + FBS + metabolic support). Stable cell lines in which the expression of the integrated transgene, either H3.3K27WT or H3.3K27M, under the control of doxycycline were generated by transfecting pINTO-NFH vector (40) . Stable cell lines were selected using 200 µg/mL zeocin and 10 µg/mL blasticidin selectable markers encoded in the pINTO-NFH vector. Stable integration was subsequently confirmed by Sanger sequencing. To induce expression of the H3.3K27WT or H3.3K27M transgenes, 1 µg/mL of doxycycline was added at the appropriate time point prior to harvesting.
A derivative of HEK-293 TREX suitable for PRC2 purification was generated as follows. A 6xHIStagged EZH2 cDNA and FLAG-tagged EED cDNA were subcloned into the pLVX-EF1alpha-IRES-mCherry lentiviral vector (Clontech). Cells stably expressing both 6xHIS-EZH2 and FLAG-EED cDNAs were generated by lentiviral transduction. For the production of viral particles, lentiviral vectors were co-transfected with pcREV, BH10, and pVSV-G into HEK-293 TREX cells. The virus-containing medium was collected 48 hr after transfection. The viruses carrying 6xHIS-EZH2 or Flag-EED were mixed in a 1:1 ratio prior to infection of 293 TREX cells. Polybrene was added to the viral medium at a concentration of 8 ug/mL. Infected cells were selected using mCherry expression by FACS sorting.
Purification of recombinant proteins
To purify the human PRC2 core complex, FLAG-tagged-EED, 6xHIS-tagged-EZH2, SUZ12, and RBAP48 were cloned into the baculovirus expression vector pFASTBac1 (Invitrogen). Recombinant PRC2 was produced in SF9 cells grown in SF-900 III SFM (Invitrogen). After 60 hr of infection, SF9 cells were resuspended in BC150 (25 mM Hepes-NaOH, pH 7.8, 1 mM EDTA, 150 mM NaCl, 10% glycerol and 1 mM DTT) with 0.1% NP40 and protease inhibitors (1 mM PMSF, 1 mM Benzamidine, 1 µg/ml Pepstatin A, 1 µg/ml Leupeptin and 1 µg/ml Aprotinin). Cells were lysed by sonication (Fisher Sonic Dismembrator model 100), and PRC2 complexes were purified through Ni-NTA agarose beads (Qiagen), FLAG-M2 agarose beads (Sigma), and Q Sepharose beads (GE healthcare).
Purification of PRC2 from 293 TREX
After expressing H3.3K27M or H3.3K27WT using 1 µg/mL of doxycycline for 72 hr, cells grown in 40x15 cm plates were harvested for each condition. Nuclei were purified using a standard hypotonic lysis approach and nuclear extract was prepared using BC400 buffer (20 mM Tris, pH 7.9, 400 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, 20% glycerol, 0.05% NP-40, 1 mM PMSF, 1 mM Benzamidine, 1 µg/ml Pepstatin A, 1 µg/ml Leupeptin and 1 µg/ml Aprotinin). The first purification step utilized Ni-NTA-agarose beads to purify EZH2 which had a 6xHis tag, followed by Q-Sepharose. The eluate was then further purified using FLAG-M2 agarose beads to isolate the complex containing FLAG-tagged EED, followed by another Q-Sepharose. PRC2 was eluted in BC500 (20 mM Hepes NaOH, pH 7.8, 500 mM NaCl, 0.02% NP-40, 10% glycerol, 1 mM PMSF and 1 mM Benzamidine). Components of purified PRC2 were visualized by silver staining after SDS-PAGE and its activity gauged in HMT assays. PRC2 was also purified from 293 cells containing FLAG-tagged EED, but not 6xHis tagged EZH2 using FLAG-M2 agarose and Q-Sepharose.
Nucleosome reconstitution
Purification of recombinant histones, refolding recombinant octamers, and reconstitution of nucleosomes were generated as described previously (25) .
Histone methyltransferase assay (HMT)
Standard HMT assays were performed as described (25) All reaction mixtures were incubated for 60 min at 30 °C and stopped by the addition of 4 μL SDS buffer (0.2 M Tris-HCl, pH 6.8, 20% glycerol, 10% SDS, 10 mM β-mercaptoethanol and 0.05% Bromophenol blue). After HMT reactions, samples were incubated for 5 min at 95 °C and resolved on SDS-PAGE gels. The gels were then subjected to Coomassie blue staining for protein visualization or wet transfer of proteins to 0.45 μm PVDF membranes (Millipore). The radioactive signals were detected by exposure on autoradiography films (Denville scientific).
PRC2 Quantitation by Mass-spectrometry
Cell Lysate Preparation. Cells were harvested by counting each cell line in quadruplicate and resuspended in a known volume of lysis buffer (8 M Urea, 1 % CHAPS and 20 mM HEPES, pH 8.0). The suspension was pulsed 6x with a sonic dismembrator on ice and rotated end over end for 1 hr at 4 o C. DNA was pelleted and cell lysate was prepared for mass-spec analysis.
Cell lysates were prepared using the filter-aided sample preparation (FASP) method. Briefly, 50 -200 μg of protein per sample, at 1 -10 μg/μl concentration, was reduced with DTT (final concentration 3 mM) at 57 o C for 1 hr and loaded onto a Microcon 30 kDa centrifugal filter unit pre-equilibrated with 200 μl of FASP buffer A (8 M urea and 0.1 M Tris HCl, pH 7.8) (Millipore). Following three washes with FASP buffer A, lysates were alkylated on filter with 50 mM iodoacetamide, 45 min in the dark. Filter bound lysates were then washed 3 times with FASP buffer A, 3 times with FASP buffer B (100 mM ammonium bicarbonate, pH 7.8) and digested overnight at RT with trypsin (Promega) at a 1:100 ratio of enzyme to protein. Peptides were eluted twice with 0.5 M NaCl. Tryptic peptides were desalted using an Ultra-Micro Spin Column, C18, (Harvard Apparatus) and the desalted peptide mixture was concentrated in a SpeedVac concentrator.
Targeted Mass Spectrometry Assay Development. Peptides for use in this assay were selected based on a series of experiments. First, we compiled data from the Global Proteome Machine Database (GPMDB) for each of the three proteins (41) . GPMDB is a repository of the results of mass spectrometry based proteomics experiments. The data collected included the peptides identified, the charge states identified, their uniqueness to the protein, and the number of times each was identified. The most often identified unique peptides and charge states of EED, EZH2, and SUZ12 were compared to the results of the recombinant analysis to generate a list of approximately 5 candidate peptides per protein.
Next, an equal molar trypsin digested mixture of the three recombinant mouse PRC2 proteins (EED, EZH2, and SUZ12) was analyzed on the Q Exactive mass spectrometer (Thermo Scientific) using a data dependent method. A list of identified proteotypic peptides was compiled. This list of peptides was used to generate a target list in the Skyline software, which was used to build the targeted MS2 method. An aliquot of a mESC lysate was analyzed using this method. Raw files were uploaded to the Skyline software. Candidate peptides were evaluated based on the chromatographic peak shape, ionization efficiency, coverage of fragmentation, level of interference from other peptides within the isolation window and the presence of product ions that differentiate the endogenous and heavy labeled peptide. 2 -3 of the strongest candidate peptides were custom synthesized (New England Peptide) with an isotopically heavy C-terminal residue.
Targeted Mass Spectrometry Analysis. The peptides were spiked into an aliquot of the cell lysate at a level ranging from 100 amoles to 5 fmoles. The peptide mixture was loaded onto an Acclaim PepMap trap column in line with an EASY-Spray 50 cm x 75 µm ID PepMap C18 analytical HPLC column with 2 μm bead size using the auto sampler of an EASY-nLC 1000 HPLC (Thermo Scientific). The peptides were gradient eluted into a Q Exactive (Thermo Scientific) mass spectrometer using a 60 min gradient from 5% to 23% solvent B (Solvent A: 2% acetonitrile, 0.5% acetic acid; Solvent B: 90% acetonitrile, 0.5% acetic acid), followed by 20 min from 23% to 45% solvent B. Solvent B was taken to 100% in 10 min and held at 100% for 20 min. High resolution full MS spectra were acquired with a resolution of 70,000, an AGC target of 1e6, with a maximum ion time of 120 ms and scan range of 300 to 1500 m/z. Following each full MS scan, targeted high resolution HCD MS/MS spectra were acquired based on the inclusion list containing the m/z values of the unlabeled endogenous and stable isotope labeled standard PRC2 peptides. All MS/MS spectra were collected using the following instrument parameters: resolution of 17,500, AGC target of 2e5, maximum ion time of 120 ms, one microscan, 2.0 m/z isolation window, fixed first mass of 150 m/z, and Normalized Collision Energy (NCE) of 27. Peptides not behaving linearly in lysate were excluded from future quantitation.
Quantitative experiments were conducted in two ways: 1) 5 point calibration curve (500 amole to 5 fmole) of standard peptides spiked into a constant amount of lysate or 2) a single point calibration of standard peptides spiked into a constant amount of lysate in triplicate in a concentration close or equal to the endogenous level.
Data Analysis and validation. Raw files were uploaded to Skyline (64 bit) software version 3.6.0.10162 for analysis. The top three or four product ions were used to quantify the light (endogenous) and stable isotopelabeled standard peptides. Total product ion area values were calculated for the light and heavy peptides.
When a calibration curve was generated, the total product ion area values for each of the stable isotopelabeled standard peptides was plotted, a linear trendline was fit to the data and the line equation was used to calculate the fmoles of endogenous peptide in the lysate. The average, standard deviation and the coefficient of variance across the triplicates is reported for all lysates.
To calculate the number of each PRC2 subunit (EZH2, EED and SUZ12) per cell, the average fmole for each peptide quantified of that subunit was computed and converted to number of molecules using Avogadro's number and divided by the number of cells analyzed to obtain molecules per cell. Total PRC2 per cell was calculated by taking the average of all subunits.
A few attempts have been made to infer the number of PRC2 molecules per nucleus using a variety of imaging and enzyme kinetic techniques. Reports vary from numbers as low as 6,000 [(ALL/myeloma; (42) ] to ~40,000 [(Drosophila neuroblast; (43) ] and as high as 20,006,965 in Drosophila salivary gland (44) . While our methods provided slight variations on these numbers, they are well within the range and ordinal differences reported, adding validity to these various methods of PRC2 quantitation.
Histone Extraction, Mass-Spectrometry and Analysis of Histone Modifications
Histone extraction, mass-spectrometry and analysis of histone modifications were based on previously published methods (45, 46) .
ChIP-seq Experiments
ChIP was performed as described previously (40) . Briefly, H3.3K27M was induced by 1 ug/mL doxycycline for 72 hr, cross-linked with 1% formaldehyde and harvested following glycine treatment to quench the formaldehyde. Nuclei were extracted, sonicated using a Diagenode Bioruptor to produce chromatin fragments at an average size of 300-500 bp. Chromatin was then precleared with BSA blocked magnetic Dynabeads. Each ChIP was performed with an internal spike-in standard corresponding to 1:200 of cross-linked, sonicated and pre-cleared Drosophila chromatin. The Drosophila-specific H2A.V antibody was also added at ~1:20 of the primary ChIP antibody. The immunoprecipitation was performed using antibodies to the appropriate protein (Table S2 ) and 30 uL of BSAblocked Dynabeads. Immunoprecipitated chromatin bound to the beads was then washed in RIPA buffer. Chromatin was de-crosslinked and proteins removed by proteinase K. DNA libraries were constructed, barcoded as in (17) and subjected to SR50 sequencing on an Illumina HiSeq2500 or Illumina NextSeq 500. Spike-in normalization was achieved using Drosophila Melanogaster DNA aligned to Illumina igenomes dm3 as mentioned above (51) . Endogenous and exogenous scaling factors were computed from the bam files (1/(number_mapped_reads/1000000)). Endogenous scaling factors were applied to the data before input subtraction (without scaling). The RPM normalization was then reversed before scaling with exogenous factors. The scripts used to perform spike-in scaling have been integrated in a bioconductor package ChIPSeqSpike (https://bioconductor.org/packages/3.7/bioc/html/ChIPSeqSpike.html). (A) H3K36me2 levels are significantly higher in H3K27M DIPG (n=2 for H3.1K27M and n=2 for H3.3K27M) than in WT DIPG/GLIOMA (H3K27WT cortical glioma n=4, H3K27WT DIPG n=2), as revealed by MS (see fig. S7 ). Data Plotted as Mean±SEM. (B) H3K36me2 ChIP-seq performed with glioma cell lines bearing either WT histone H3 (n=2 total) or H3K27M, as indicated (n=2; see Table S1 for details). The left trend plot was generated by first identifying genes that displayed significant H3K36me2 enrichment above input for the H3K27M-bearing DIPG XIII cell line (1,727 genes). Subsequently, average H3K36me2 levels were plotted for each glioma cell line across those genes (transcriptional start to end site). As a control, H3K36me2 was plotted over all genes in the genome (right). Combined, H3K36me2 enriched genes in the H3K27M-DIPG showed overall higher levels of H3K36me2 relative to glioma with WT histone H3. (C) Representative ChIP-seq tracks show generally elevated levels of H3K36me2 across these genes in H3K27M DIPG. Variations of the effect can be seen in these gliomas: some genes devoid of H3K36me2 in H3WT gain H3K36me2 in H3K27M, while others contain H3K36me2 in both H3WT and H3K27M glioma, yet the levels in the H3K27M lines are generally higher. Table S1 . Tumor samples and cell lines used in this study. 
ChIP-seq Data Processing
SUPPLEMENTARY MATERIALS
